CClinicalTrials.gg
CompletedNCT05285306PEACEUpdated May 11, 2023

Surveillance Pelvic Examination Anxiety: Brief Coping Skills Intervention

An interventional study of PEACE Program in Anxiety, sponsored by Duke University. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by Duke University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this study is to test the feasibility and acceptability of a brief coping skills training program addressing anxiety and pain related to surveillance pelvic examinations for female gynecologic cancer survivors.

Read the detailed description

The investigators have developed and manualized a coping skills training intervention for female gynecologic cancer patients that aims to reduce anxiety related to surveillance pelvic examinations (Pelvic Examination and Anxiety Coping Skills for Empowerment: PEACE). The investigators propose a proof-of concept pilot study to evaluate the acceptability and feasibility of the coping skills intervention. The study will be conducted by Duke University. Participants (N=16) will receive the 3-session telemedicine coping skills intervention. Participants will complete assessments at baseline, post-intervention (within 2 weeks before their next scheduled pelvic examination), and post pelvic examination (2-3 months after the baseline assessment). Study aims are: Aim 1) Assess intervention acceptability and feasibility through quantitative measurement and qualitative feedback from semi-structured interviews, and Aim 2) Graphically depict patterns of change in outcome variables and intervention targets.

02

Conditions studied

  • Anxiety

Browse trials for

03

In context

Anxiety Disorders

4,868 studies on the registry are indexed under Anxiety Disorders; 1,390 are open to participants now.

This study's enrollment of 16 is below the median of 80 across 4,174 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Duke University is the lead sponsor of 2,025 studies on the registry; 275 are open to participants now.

Of its 194 completed or terminated interventional studies of FDA-regulated products, 159 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • female sex
  • diagnosis of stage I-IV cervical or endometrial cancer
  • 18 years of age or older
  • able to speak/read English
  • able to give informed consent
  • completed cancer treatments within 2-24 months prior to enrollment, and recommended to undergo surveillance pelvic examination at three month intervals
  • able to commit to three 45-60 minute visits within the study period
  • able to participate in the intervention via the telemedicine modality (e.g., phone or video)

Exclusion criteria

Exclusion Criteria:

  • unable to provide informed consent
  • major untreated or uncontrolled mental illness
  • hearing impairment that impedes telephone or video calls
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    PEACE Program

    3 sessions of tailored coping skills related to pelvic examinations

    Behavioral: PEACE Program

Interventions

  • BehavioralPEACE Program

    This pilot will consist of 3 individual telemedicine sessions to teach cognitive behavioral coping skills and provide education related to gynecologic cancer surveillance and psychological distress.

    Also known as: Pelvic Exam and Anxiety Coping Skills for Empowerment

06

What researchers measure

Primary outcomes

  1. Intervention acceptability will be assessed using an adapted version of the Satisfaction with Therapy and Therapist Scale (STTS-R)

    The adapted STTS-R consists of 18 items that assess satisfaction with the therapist and the intervention on a 5-point Likert-type scale from 1 (strongly disagree) to 5 (strongly agree).

    Time frame: post pelvic examination (approximately 2-3 months after baseline)

  2. Change in intervention acceptability will be assessed using an adapted version of the Satisfaction with Therapy and Therapist Scale (STTS-R)

    Change in intervention acceptability from immediately after completion of the 3 sessions (post intervention assessment) to after trying to implement the coping skills during their next pelvic examination (post pelvic exam assessment), using the STTS-R. The adapted STTS-R consists of 18 items that assess satisfaction with the therapist and the intervention on a 5-point Likert-type scale from 1 (strongly disagree) to 5 (strongly agree).

    Time frame: post-intervention (within 2 weeks of their next pelvic examination), post pelvic examination (approximately 2-3 months after baseline)

  3. Intervention feasibility as measured by percentage of recruited participants who enrolled

    Enrollment logs will capture the number of participants who were recruited and among them, the number that enrolled in the study.

    Time frame: post pelvic examination (approximately 2-3 months after baseline)

  4. Intervention feasibility as measured by attrition

    Retention logs will capture the number of participants who did not complete the study protocol (rate of attrition)

    Time frame: post pelvic examination (approximately 2-3 months after baseline)

  5. Intervention feasibility as measured by survey completion

    Retention logs will capture the number of participants who completed all assessments

    Time frame: post pelvic examination (approximately 2-3 months after baseline)

  6. Intervention feasibility as measured by home practice completion

    Interventionist logs completed at the conclusion of each session will capture the level of home practice completion

    Time frame: post-intervention (within 2 weeks of their next pelvic examination)

  7. Intervention feasibility as measured by participant engagement

    Interventionist logs completed at the conclusion of each session will capture the level of participant engagement with a 1 item question rated from 1 (not at all engaged) to 4 (highly engaged).

    Time frame: post-intervention (within 2 weeks of their next pelvic examination)

  8. Intervention feasibility as measured by interventionist fidelity

    Fidelity rating forms will be used to measure the level of fidelity to session content for one third of the sessions for the protocol. Each component of the session will be rated from 0 (not covered at all) to 3 (thoroughly covered the topic)

    Time frame: post-intervention (within 2 weeks of their next pelvic examination)

Secondary outcomes

  1. Change in anxiety related to examination as measured by the The State Anxiety Scale of the State-Trait Anxiety Inventory

    The State Anxiety Scale of the STAI is comprised of 20 items on a 5-point Likert scale, which range from 1 (not at all) through 4 (very much).

    Time frame: baseline, post-intervention (within 2 weeks of their next pelvic examination), post pelvic examination (approximately 2-3 months after baseline)

  2. Change in pain during examination as measured by numeric scales

    Numeric scales will be used to assess the average pain during examination, worst pain during examination, and lowest pain during examination, ranging from 0 (no pain) to 10 (pain as bad as you could imagine). The three pain intensity ratings will be averaged to create a total score for pain.

    Time frame: baseline, post pelvic examination (approximately 2-3 months after baseline)

07

Study locations

1 site
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05285306
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Mar 21, 2022
Primary completion
Sep 2, 2022
Completion
Sep 2, 2022
Last update
May 11, 2023

Study contacts

Rebecca Shelby, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion